Search results for "Therapy."

showing 10 items of 12240 documents

Abemaciclib: safety and effectiveness of a unique cyclin-dependent kinase inhibitor

2020

Introduction: The discovery and the clinical availability of novel cyclin-dependent kinases 4 and 6 inhibitors have profoundly changed the therapeutic scenario of metastatic hormone receptor-positive breast carcinoma. Among these inhibitors, abemaciclib can induce potent and sustained cell cycle arrest and immune system stimulation. Areas covered: This review summarizes the safety profile and clinical efficacy data on abemaciclib alone or in combination with aromatase inhibitors or fulvestrant in metastatic hormone receptor-positive breast carcinoma. The management of patients treated with abemaciclib is the object of this paper. Expert opinion: As shown in phase 2 and 3 clinical trials on …

safetyAminopyridinesBreast Neoplasms030204 cardiovascular system & hematology03 medical and health scienceschemistry.chemical_compoundabemaciclib breast cancer metastases hormonal receptors safetybreast cancer0302 clinical medicineBreast cancerCyclin-dependent kinaseAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansPharmacology (medical)metastasesskin and connective tissue diseasesFulvestrantProtein Kinase InhibitorsAbemaciclibbiologyAromatase Inhibitorsbusiness.industryKinasehormonal receptorsCyclin-Dependent Kinase 4Cell Cycle CheckpointsCyclin-Dependent Kinase 6General Medicinemedicine.diseaseAbemaciclibchemistry030220 oncology & carcinogenesisQuality of LifeCancer researchbiology.proteinBenzimidazolesFemalesense organsbusinessHormone
researchProduct

Safety and immunogenicity of the PRAME cancer immunotherapeutic in metastatic melanoma: results of a phase I dose escalation study

2016

Purpose The PRAME tumour antigen is expressed in several tumour types but in few normal adult tissues. A dose-escalation phase I/II study (NCT01149343) assessed the safety, immunogenicity and clinical activity of the PRAME immunotherapeutic (recombinant PRAME protein (recPRAME) with the AS15 immunostimulant) in patients with advanced melanoma. Here, we report the phase I dose-escalation study segment. Patients and methods Patients with stage IV PRAME-positive melanoma were enrolled to 3 consecutive cohorts to receive up to 24 intramuscular injections of the PRAME immunotherapeutic. The RecPRAME dose was 20, 100 or 500 µg in cohorts 1, 2 and 3, respectively, with a fixed dose of AS15. Advers…

safetyCancer Researchmedicine.drug_classmedicine.medical_treatmentMedizinPhases of clinical research[SDV.CAN]Life Sciences [q-bio]/CancerimmunogenicityImmunostimulant03 medical and health sciences0302 clinical medicine[SDV.CAN] Life Sciences [q-bio]/CancerCancer immunotherapymedicine1506030304 developmental biologyOriginal ResearchPRAME antigen0303 health sciencesPRAMEcancer immunotherapybusiness.industryMelanomaImmunogenicityCancermedicine.disease3. Good healthOncology030220 oncology & carcinogenesisImmunologyChillsmedicine.symptombusinessmetastatic melanoma
researchProduct

Safety and immunogenicity of the therapeutic vaccine TG1050 in chronic hepatitis B patients: a phase 1b placebo-controlled trial

2020

Funding: Transgène; International audience; Treatment of chronic hepatitis B (CHB) typically requires life-long administration of drugs. Cohort and pre-clinical studies have established the link between a functional T-cell-mounted immunity and resolution of infection. TG1050 is an adenovirus 5-based vaccine that expresses HBV polymerase and domains of core and surface antigen and has shown immunogenicity and antiviral effects in mice. We performed a phase 1 clinical trial to assess safety and explore immunogenicity and early efficacy of TG1050 in CHB patients. This randomized, double blind, placebo-controlled study included two sequential phases: one single dose cohort (SD, n = 12) and one …

safetyHBsAg030231 tropical medicineImmunologyPlacebo-controlled studyPhases of clinical researchSciences du Vivant [q-bio]/Médecine humaine et pathologieimmunogenicityPlaceboAntiviral AgentsAdenoviridae03 medical and health sciencesMice0302 clinical medicineHepatitis B ChronicImmunogenicity VaccinevaccineImmunology and AllergyMedicineAnimalsHumans030212 general & internal medicineAdverse effectPharmacologyVaccinesHepatitis B Surface Antigens[SDV.MHEP] Life Sciences [q-bio]/Human health and pathologybusiness.industryELISPOTImmunogenicitychronicityimmuno-therapyHepatitis Bmedicine.diseaseHepatitis B3. Good healthImmunologybusiness[SDV.MHEP]Life Sciences [q-bio]/Human health and pathologyResearch Paper
researchProduct

Tenapanor for the treatment of irritable bowel syndrome with constipation.

2020

Introduction: Irritable bowel syndrome with constipation is associated with higher rates of functional impairment, as compared to other subtypes of the syndrome. Conventional laxative-based pharmacologic therapy of IBS-C, which is mostly symptom-based, is often unsatisfactory. Tenapanor represents a first-in-class orally available inhibitor of NHE3, which is minimally absorbed in the GI tract, what constitutes a significant therapeutic benefit, as it may act on the drug target. Areas covered: Aim of this article is to sum up the evidences about pharmacodynamics and pharmacokinetics of tenapanor, focusing on animal models and in vitro studies, but also discuss clinical trials on tenapanor's …

safetymedicine.medical_specialtyFunctional impairmentConstipationmedicine.medical_treatmentefficacyLaxative030226 pharmacology & pharmacyGastroenterologyIrritable Bowel Syndrome03 medical and health scienceschemistry.chemical_compound0302 clinical medicineGastrointestinal AgentsInternal medicinemedicineAnimalsHumansPharmacology (medical)Pharmacologic therapyDrug InteractionsGeneral Pharmacology Toxicology and PharmaceuticsTenapanorIrritable bowel syndromeSulfonamidesbusiness.industrySodium-Hydrogen Exchanger 3General Medicinemedicine.diseaseIsoquinolinestenapanor.chemistry030220 oncology & carcinogenesismedicine.symptombusinessConstipationExpert review of clinical pharmacology
researchProduct

High training volume is associated with increased prevalence of non-allergic asthma in competitive cross-country skiers.

2022

BackgroundCross-country skiers have a high prevalence of asthma, but its phenotypes and association with success in competitions are not known.ObjectiveTo investigate, by means of a postal survey, the relative proportions of allergic and non-allergic asthma in competitive cross-country skiers compared with the general population, to study how performance level and training volume are related to asthma and its type and to assess the possible risk factors for allergic and non-allergic asthma in competitive skiers.MethodsAll Finnish cross-country skiers enrolled in the largest national competitions in winter 2019 (n=1282), and a random sample (n=1754) of the general population of the same age …

sairastavuusprevalencePhysical Therapy Sports Therapy and Rehabilitation3121 Internal medicinerespiratory tract diseaseshiihtäjät3141 Health care scienceimmune system diseasesnon-allergic asthmaastmaharjoitteluOrthopedics and Sports Medicinecross-country skiershengityselinten taudit315 Sport and fitness scienceshuman activitieshigh training volumehuippu-urheilijatBMJ open sportexercise medicine
researchProduct

Double blind randomized clinical trial comparing minimally- invasive envelope flap and conventional envelope flap on impacted lower third molar surge…

2022

The latest trend in surgery is to look for minimally invasive procedures, with fewer complications and a shorter recovery time. This study aims to compare the minimally- invasive envelope flap, with smaller incision and fewer dissection and the conventional envelope flap, with a 20mm incision, on impacted mandibular third molar surgery, focusing on the hypothesis that there were no differences in postoperative outcomes. A double-blind randomized clinical trial was designed to compare both incisions, focused on determining the approach with minor postoperative side-effects and minor impact on quality-of-life. A total of 60 patients were enrolled for the study if their presented impacted mand…

salivaPain Postoperativetranscultural validationAdolescentTooth ImpactedMandiblexerostomia questionnairePostoperative ComplicationsOtorhinolaryngologyTooth ExtractionQuality of LifeHumansEdemahead and neck cancerMolar ThirdTrismusSurgeryxerostomiaGeneral DentistryradiotherapyUNESCO:CIENCIAS MÉDICASMedicina Oral Patología Oral y Cirugia Bucal
researchProduct

The Use of Lenograstim in the prevention of chemotherapy induced neutropenia in patiets with soft tissue sarcoma (STS)

2008

sarcoma chemotherapy neutropenia
researchProduct

Effects of low laser level therapy in rehabilitation of patients with COVID19 pneumonia

2021

Introduction. An unprecedented public health crisis has been triggered worldwide by SARS-CoV-2’s high contagiosity and it’s mortality rates of 1-5%. Although the majority of COVID-19 cases have a good outcome, there is a small percentage that develop severe pneumonia and citokine storm and may be in the need of mechanical ventilation. Methods. Identifying the exact drivers of the excessive inflammation and the biomarkers that can predict a hyperinflammatory response to SARS-CoV-2 would be extremly helpful in finding efficient anti-inflammatory interventions that may stop the progression to acute respiratory distress syndrome (ARDS). Results. In the search for such interventions we have iden…

sars-cov-2anti-inflammatory effectcitokine stormScienceQpneumonialow laser level therapyGeneral Medicinerespiratory tract diseasesBalneo and PRM Research Journal
researchProduct

Rat Cardiac progenitor cells and their application in cell therapy

2015

cells and the subsequent heart failure. When the pharmacological approach no longer complies with the disease evolution, organ transplantation appears to be the only treatment able to rescue the patient life. Cell therapy promises to be clinically efficient and would allow circumventing many limitations of organ transplantation, such as organ low availability, major surgical procedures, high costs and longterm immunosuppression [1]. We designed porous Poly-Lactic Acid (PLLA) and Fibroin scaffolds to deliver CPCs in the heart, we isolated and characterized CPCs for the expression of c-Kit, MDR-1 and Sca-1 by flow cytometry, we tested their degree of differentiation in vitro studying the expr…

scaffold heart cardiac stem cellsCardiac progenitor cells; biomaterials; cell therapy.
researchProduct

Unique Problems Require Unique Solutions—Models and Problems of Linking School Effectiveness and School Improvement

2022

The article aims to outline the proposals for linking school effectiveness research and school improvement that are currently relevant in international discussion and to ask how they deal with the ‘technology deficit’ at the level of model improvement. We will first show the difference between school improvement and school effectiveness. Then, we outline areas showing basic problems associated with linking school effectiveness and school improvement. After that, we present a summary of two relevant models for linking school effectiveness research and school improvement—Comprehensive Framework of Effective School Improvement and Dynamic Model of Educational Effectiveness&md…

school effectiveness; school improvement; educational effectiveness research; linking; linkage; school improvement researchPublic AdministrationDevelopmental and Educational PsychologyComputer Science (miscellaneous)Physical Therapy Sports Therapy and RehabilitationEducationComputer Science ApplicationsEducation Sciences; Volume 12; Issue 3; Pages: 158
researchProduct